Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90. doi: 10.1073/pnas.1208984109. Epub 2012 Jun 27.
A large number of anti-HIV-1 antibodies targeting the CD4-binding site (CD4bs) on the envelope glycoprotein gp120 have recently been reported. These antibodies, typified by VRC01, are remarkable for both their breadth and their potency. Crystal structures have revealed a common mode of binding for several of these antibodies; however, the precise relationship among CD4bs antibodies remains to be defined. Here we analyze existing structural and sequence data, propose a set of signature features for potent VRC01-like (PVL) antibodies, and verify the importance of these features by mutagenesis. The signature features explain why PVL antibodies derive from a single germ-line human V(H) gene segment and why certain gp120 sequences are associated with antibody resistance. Our results bear on vaccine development and structure-based design to improve the potency and breadth of anti-CD4bs antibodies.
大量针对包膜糖蛋白 gp120 上的 CD4 结合位点 (CD4bs) 的抗 HIV-1 抗体最近已经被报道。这些抗体,以 VRC01 为代表,其特点是具有广谱性和高效性。晶体结构揭示了其中几种抗体的一种共同结合模式;然而,CD4bs 抗体之间的确切关系仍有待确定。在这里,我们分析了现有的结构和序列数据,提出了一组强效 VRC01 样 (PVL) 抗体的特征,并通过突变来验证这些特征的重要性。这些特征解释了为什么 PVL 抗体来源于单一的人类 V(H) 基因片段,以及为什么某些 gp120 序列与抗体耐药性相关。我们的研究结果对疫苗开发和基于结构的设计具有重要意义,有助于提高抗 CD4bs 抗体的效力和广谱性。